WHOCC
Postal address:
WHO Collaborating Centre for Drug Statistics Methodology
Norwegian Institute of Public Health
Postboks 222 Skøyen
0213 Oslo
Norway

Visiting/delivery address:
Sandakerveien 24C
Bygg C
0473 Oslo
Norway

Tel:  +47 21 07 81 60
E-mail:
 
Copyright/Disclaimer

New ATC codes 2021

New ATC codes 2021

New DDDs 2021
ATC/DDD alterations 2021

ATC codeATC level name
A03AX15menthae piperitae aetheroleum
A05BA09metadoxine
A06AX08tenapanor
A10BD26metformin and lobeglitazone
A10BG04lobeglitazone
A10BH08teneligliptin
A10BJ07beinaglutide
A10BK07luseogliflozin
A16AX16givosiran
A16AX17triheptanoin
A16AX18lumasiran
A16AX30sodium benzoate and sodium phenylacetate
B03AD05ferrous gluconate
B05XA18zinc sulfate
B06AX02betibeglogene autotemcel
C01DX22vericiguat
C09BX05ramipril and bisoprolol
C10AX16inclisiran
C10BA10bempedoic acid and ezetimibe
C10BX18atorvastatin, amlodipine and ramipril
D01BA03fosravuconazole
D05AX55tazarotene and ulobetasol
D06BX03tirbanibulin
D10AF07minocycline
D11AH07tralokinumab
D11AX26caffeine
G02CX05bremelanotide
G03AA18drospirenone and estetrol
H01AC07somapacitan
H01CC54relugolix, estradiol and norethisterone
H02CA03 1)ketoconazole
H05AA04abaloparatide
H05BX05 2)calcifediol
J01DH56imipenem, cilastatin and relebactam
J01DI04cefiderocol
J01MA24levonadifloxacin
J01MA25lascufloxacin
J04AK08pretomanid
J05AJ04cabotegravir
J05AX28bulevirtide
J05AX29fostemsavir
J07BB04influenza, virus like particles
J07BX02ebola vaccines
L01EE04selumetinib
L01EH03tucatinib
L01EL03zanubrutinib
L01EM04duvelisib
L01EX15pexidartinib
L01EX16erdafitinib
L01EX17capmatinib
L01EX18avapritinib
L01EX19ripretinib
L01EX20pemigatinib
L01EX21tepotinib
L01XC34moxetumomab pasudotox
L01XC35tafasitamab
L01XC36enfortumab vedotin
L01XC37polatuzumab vedotin
L01XC38isatuximab
L01XC39belantamab mafodotin
L01XC40dostarlimab
L01XC41trastuzumab deruxtecan
L01XK05veliparib
L01XX69lurbinectedin
L01XX70axicabtagene ciloleucel
L01XX71tisagenlecleucel
L01XY02pertuzumab and trastuzumab
L04AA45filgotinib
L04AA46itacitinib
L04AA47inebilizumab
L04AC19satralizumab
M02AA29esflurbiprofen
M09AX08golodirsen
M09AX09onasemnogene abeparvovec
M09AX10risdiplam
M09AX11palovarotene
N01BB59bupivacaine and meloxicam
N02AA11oxymorphone
N02BG11mirogabalin
N03AX25cenobamate
N03AX26fenfluramine
N04CX01istradefylline
N05CD15nimetazepam
R01AD59mometasone, combinations
R07AX32ivacaftor, tezacaftor and elexacaftor
S01GA07brimonidine
S01LA07abicipar pegol
1) Oral formulations only indicated in treatment of Cushing’s
2) Oral formulations only indicated in treatment of renal secondary hyperparathyroidism

New ATC 3rd and 4th levels

ATC codeATC 3rd and 4th level name
J05AJIntegrase inhibitors
L01CETopoisomerase 1 (TOP1) inhibitors
L01EPROTEIN KINASE INHIBITORS
L01EABCR-ABL tyrosine kinase inhibitors
L01EBEpidermal growth factor receptor (EGFR) tyrosine kinase inhibitors
L01ECB-Raf serine-threonine kinase (BRAF) inhibitors
L01EDAnaplastic lymphoma kinase (ALK) inhibitors
L01EEMitogen-activated protein kinase (MEK) inhibitors
L01EFCyclin-dependent kinase (CDK) inhibitors
L01EGMammalian target of rapamycin (mTOR) kinase inhibitors
L01EHHuman epidermal growth factor receptor 2 (HER2) tyrosine kinase inhibitors
L01EJJanus-associated kinase (JAK) inhibitors
L01EKVascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitors
L01ELBruton's tyrosine kinase (BTK) inhibitors
L01EMPhosphatidylinositol-3-kinase (Pi3K) inhibitors
L01EXOther protein kinase inhibitors
L01XFRetinoids for cancer treatment
L01XGProteasome inhibitors
L01XHHistone deacetylase (HDAC) inhibitors
L01XJHedgehog pathway inhibitors
L01XKPoly (ADP-ribose) polymerase (PARP) inhibitors
N04COTHER ANTIPARKINSON DRUGS
N04CXOther antiparkinson drugs

Last updated: 2021-01-04